RUTI Immune

RUTI Immune (legally Immuni Therapeutics, S.L.) is a Spanish biotechnology company founded in 2020 as a spin-off from Archivel Farma. The company is dedicated to developing the RUTI® vaccine technology—originally designed for tuberculosis—as a broad-spectrum antiviral treatment and prophylaxis, with an initial focus on COVID-19. Its core innovation lies in trained innate immunity, which primes the body's non-specific immune system to respond more effectively to various viral pathogens and mutations. Headquartered in Badalona, RUTI Immune leverages the GMP manufacturing capabilities of its parent company to advance its clinical programs. The company has successfully utilized crowdfunding platforms like Capital Cell to finance its research and development efforts.